We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
3.40 | 0.20% | 1,708.60 | 1,708.60 | 1,708.80 | 1,713.00 | 1,699.40 | 1,701.60 | 11,522,668 | 16:29:59 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.27 | 70.34B |
Date | Subject | Author | Discuss |
---|---|---|---|
06/6/2022 11:41 | Trying to understand how it can be in Pfizer's interest to announce before the float that they are going to dispose of their third of Haleon at the earliest opportunity. Although they will be forced to wait a few months, this must have a significant effect on the initial price. Not so? | jonjoneil | |
06/6/2022 11:40 | It'll just be nodded through. | keyno | |
06/6/2022 11:32 | It's 467 pages! But most of it is of little interest to the likes of us. | anhar | |
06/6/2022 11:30 | Great thanks I'll read the propectus all ways a good idea? | jretlaw | |
06/6/2022 11:26 | The date has been given in the prospectus timetable on page 16, extract: ...Latest time and date for transfers of GSK Shares to be registered on the Register at the Shareholder Record Time 6 p.m. on 15 July 2022 Shareholder Record Time for determining the entitlement to the Demerger Dividend 6 p.m. on 15 July 2022... This assumes all the shareholder etc. formalities and perrmissions are granted according to the timetable for the demerger to take place, it being almost certain that they will. hxxps://www.gsk.com/ | anhar | |
06/6/2022 10:05 | GSK wins FDA approval for measles, mumps and rubella vaccine Priorix Mon, 6th Jun 2022 10:05 Alliance News (Alliance News) - GSK PLC on Monday said the US Food & Drug Administration has approved its Priorix vaccine for active immunisation for the prevention of measles, mumps and rubella in individuals of 12 months of age and older. The London-based pharmaceutical company said Priorix is currently licenced in more than 100 countries worldwide, including all European countries, Canada, Australia and New Zealand. More than 800 million doses of the treatment have been distributed to date, the FTSE 100 listed firm added. The safety of Priorix was evaluated in six clinical studies, in which a total of 12,151 participants received at least one dose of it. Its efficacy was demonstrated based on immunogenicity data compared to the comparator vaccine. Measles, mumps and rubella are acute and contagious viral diseases that can also lead to serious conditions including meningitis and hearing loss. "We're proud to make Priorix available in the US for the first time, adding a choice for providers to help protect patients against these highly contagious diseases and to further strengthen offerings in our paediatric vaccine portfolio," said Judy Stewart, head of US Vaccines for GSK. By Abby Amoakuh; abbyamoakuh@alliance | waldron | |
06/6/2022 08:57 | For news on Haleon (HAL), I think its best to wait for the Shareholders to vote at the General Meeting on 6 July. | tradermichael | |
06/6/2022 08:08 | Will the be an ex split date at which date we will get the entitlement to hallion | jretlaw | |
06/6/2022 08:06 | Will there be a ex split date at which one has to hold the shares upto to get halion as no mention so far in the littrature | jretlaw | |
06/6/2022 06:48 | GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Priorix (Measles, Mumps and Rubella Vaccine, Live) for active immunisation for the prevention of measles, mumps and rubella (MMR) in individuals 12 months of age and older. Priorix is currently licenced in more than 100 countries worldwide, including all European countries, Canada, Australia and New Zealand, with more than 800 million doses distributed to date. "We're proud to make Priorix available in the US for the first time, adding a choice for providers to help protect patients against these highly-contagious diseases and to further strengthen offerings in our paediatric vaccine portfolio," said Judy Stewart, Senior Vice President and Head of US Vaccines, GSK. | tradermichael | |
06/6/2022 06:21 | Another FDA approval today | ayl30 | |
05/6/2022 20:49 | Lol. Fair point net curtains. Indeed I'm not a personal friend of the original Mr Smithskline but a supporter of GSK for the last 20yrs nonetheless. | finctastic | |
05/6/2022 17:53 | Finctastic: you said: "I've held GSK since the start" That cant be true. SmithKline was founded in 1830 | netcurtains | |
05/6/2022 16:24 | I've held GSk since the start but I'm with Pfizor on this one. Get out and leave the debt if in doubt. Which there definitely is imo. | finctastic | |
04/6/2022 20:27 | Wonder what the float price will be | mj19 | |
03/6/2022 08:35 | I generally shun these demergers/consolidat | tradermichael | |
02/6/2022 08:14 | Looks like Haleon will carry the debt: Before the demerger, GSK is planning to take a dividend of more than £7bn and Pfizer more than £3bn, leaving Haleon with net debt of £10.3bn, a figure it plans to reduce over time. | tradermichael | |
01/6/2022 23:02 | Don't overlook the tracker funds that will have to own it as a FT 100 share and the only free stock will come from Pfizer for starters | ianood | |
01/6/2022 18:04 | The Pfizer intention has been known for a few months, no surprise ....;0) | tradermichael | |
01/6/2022 16:15 | It looks like renewed weakness in the US markets did for GSK this afternoon. That plus the Pfizer news - do we think that was priced in or a surprise? I hadn’t heard it before … | spyder | |
01/6/2022 15:02 | Back in the 1600s for the split then | spoole5 | |
01/6/2022 11:40 | It is not unresonable to assume that Pfizer and GSK (but especially Pfizer) would not sell shares in Haleon at a market cap of less than £50m or possibly even £60m given that they rejected a bid of £50m and said they wouldn’t sell for less than £60m. They would look a bit daft if they then cash out at £40m! | spyder |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions